Endo Launches First Generic Version of RAVICTI for Rare Urea Cycle Disorders
核心洞察
Endo (搜索) has launched the first and only FDA-approved generic version of RAVICTI (glycerol phenylbutyrate) oral liquid in the United States, providing a new treatment option for patients with urea cycle disorders (搜索).
The generic formulation serves as a nitrogen-binding agent for chronic management of both adult and pediatric patients with UCDs (搜索) who cannot be managed by dietary protein restriction alone.
This first-to-market generic launch represents a significant milestone for Endo (搜索)'s complex generics portfolio and aims to expand access for patients and healthcare providers.
Endo (搜索), a wholly-owned subsidiary of Mallinckrodt plc (搜索), announced the launch of a generic version of Amgen's RAVICTI (glycerol phenylbutyrate) oral liquid following final FDA approval for its Abbreviated New Drug Application. The 1.1 gm/mL oral liquid formulation represents the first and currently only FDA-approved generic version of RAVICTI available in the United States.
"This first-to-market launch of generic RAVICTI oral liquid is a meaningful milestone for Endo (搜索) and important for our Generics business as we near the planned spin-off of Par Health (搜索)," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions and Generics. "It expands access for patients and providers, and reinforces our commitment to quality, reliability, and leadership in complex generics."
Clinical Indication and Mechanism
Glycerol phenylbutyrate oral liquid is indicated as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (搜索) (UCDs (搜索)) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. The medication must be used in conjunction with dietary protein restriction and, in some cases, dietary supplements including essential amino acids, arginine, citrulline, and protein-free calorie supplements.
The drug's mechanism relies on exocrine pancreatic enzymes that hydrolyze glycerol phenylbutyrate in the small intestine, separating the active moiety phenylbutyrate from glycerol. This process is critical for the medication's efficacy in controlling plasma ammonia levels.
Safety Profile and Monitoring Requirements
Neurotoxicity Concerns
The most significant safety concern involves potential neurotoxicity (搜索) associated with increased exposure to phenylacetate (PAA), the major metabolite of glycerol phenylbutyrate. Signs and symptoms of PAA neurotoxicity have been reported at plasma concentrations above 500 micrograms/mL, including somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of preexisting neuropathy.
Healthcare providers must consider potential PAA neurotoxicity (搜索) when patients present with vomiting, nausea, headache, somnolence, or confusion in the absence of high ammonia or other intercurrent illness, which may necessitate dosage reduction.
Clinical Trial Safety Data
In adult patients, the most common adverse reactions occurring in at least 10% of patients during short-term treatment (4-week study, n=45) were diarrhea, flatulence, and headache. During longer-term treatment (12 months, n=51), adverse reactions included nausea, vomiting, diarrhea, decreased appetite, dizziness, headache, and fatigue.
For pediatric patients ages 2-17 years (n=26), adverse reactions reported in at least 10% included upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, and headache. In younger pediatric patients aged 2 months to less than 2 years (n=17), common adverse reactions included neutropenia, vomiting, constipation, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash, and papule.
Drug Interactions and Special Populations
The medication has several important drug interactions. Corticosteroids (搜索) may increase plasma ammonia levels by causing breakdown of body protein, requiring close monitoring when used concomitantly. Valproic acid and haloperidol may induce hyperammonemia (搜索), necessitating careful plasma ammonia level monitoring in UCD patients.
Glycerol phenylbutyrate acts as a weak CYP3A4 (搜索) inducer, potentially decreasing systemic exposure to drugs that are CYP3A4 substrates, including those with narrow therapeutic indices such as alfentanil, quinidine, and cyclosporine.
For patients with hepatic impairment, dosage should be started at the lower end of the recommended range due to potentially reduced conversion capability and higher plasma PAA ratios. The efficacy and safety in patients with renal impairment remain unknown, requiring close ammonia level monitoring when initiating treatment.
Market Impact
This launch represents a key first-to-market generic entry for Endo (搜索), reinforcing the company's focus on complex generics as it approaches the planned spin-off of Par Health (搜索). The availability of a generic version is expected to expand access for patients and healthcare providers managing this rare metabolic condition.
The medication is contraindicated in patients with known hypersensitivity to phenylbutyrate, with hypersensitivity signs including wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash. Safety and efficacy have been established in pediatric patients, though breastfeeding is not recommended during treatment due to potential serious adverse reactions including neurotoxicity (搜索) and tumorigenicity.